News stories about Krystal Biotech (NASDAQ:KRYS) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Krystal Biotech earned a news impact score of 0.05 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.9721863093976 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Separately, Ladenburg Thalmann Financial Services started coverage on Krystal Biotech in a report on Wednesday, October 18th. They set a “buy” rating and a $23.00 price objective on the stock.
Shares of Krystal Biotech (NASDAQ:KRYS) opened at $10.50 on Tuesday. Krystal Biotech has a twelve month low of $9.01 and a twelve month high of $11.98.
Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 13th. The company reported ($1.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.52). analysts forecast that Krystal Biotech will post -1.85 EPS for the current fiscal year.
In other news, COO Suma Krishnan purchased 100,000 shares of the stock in a transaction dated Friday, September 22nd. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. Following the acquisition, the chief operating officer now owns 1,935,249 shares of the company’s stock, valued at $19,352,490. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel Janney purchased 200,000 shares of the stock in a transaction dated Friday, September 22nd. The stock was purchased at an average price of $10.00 per share, with a total value of $2,000,000.00. The disclosure for this purchase can be found here.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/krystal-biotech-krys-receives-news-impact-score-of-0-05.html.
Krystal Biotech Company Profile
Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.
Receive News & Ratings for Krystal Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.